Nuvation Bio Amends Agreement with Daiichi Sankyo for Japan Rights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy NUVB?
Nuvation Bio announced the company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo to include Japan rights, effectively securing exclusive global development and commercialization rights of the investigational medicine. The agreement, as amended, enables Nuvation Bio to expand its ongoing pivotal SIGMA study of safusidenib into Japan, and provides rights to all previously generated and future data to support further publication of safusidenib results in IDH1-mutant glioma. Safusidenib is a novel, oral, potent, brain-penetrant, selective inhibitor of mutant IDH1 that is currently being evaluated in the ongoing Phase 3 SIGMA study for the maintenance treatment of patients with IDH1-mutant astrocytoma who have high-risk features following standard-of-care. In Phase 1 and Phase 2 single arm studies, safusidenib has shown encouraging efficacy signals across all IDH1-mutant glioma grades and treatment lines, including durable responses and prolonged progression-free survival that show tumor shrinkage and disease control.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.820
Low
8.00
Averages
11.38
High
18.00
Current: 4.820
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvation Bio CRO Sells 200,000 Shares Amid Strategic Options Exercise
- Insider Selling Details: Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000, reducing his direct holdings by 79.05% from 253,000 to 53,000 shares, which may raise concerns about insider confidence in the company's future prospects.
- Transaction Context: This sale followed the exercise of options, and Wentworth retains 53,000 shares along with 700,000 stock options, indicating he still holds a material economic interest in Nuvation Bio, despite the significant reduction in direct stock ownership.
- Market Reaction and Investor Sentiment: Large insider sales often alert investors; however, such transactions are common in the biotech sector, particularly when executives lock in profits through options, suggesting that market sentiment may not be significantly impacted by this sale.
- Company Financial Overview: Despite a net loss of approximately $204.6 million over the past year, Nuvation Bio's revenue from its oncology drug Ibtrozi and its diversified R&D pipeline provide potential growth opportunities for long-term investors, particularly those with a higher risk tolerance.
See More
Nuvation Bio Executive Sells 200,000 Shares
- Share Sale Details: Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000 at $4.52 per share, reducing direct ownership from 253,000 to 53,000 shares, indicating a significant divestment by an executive.
- Options Exercise and Market Reaction: The transaction involved the exercise of options with an immediate sale and no indirect entities, and while insider selling may raise market concerns, it is a planned event, suggesting that market sentiment may remain unaffected.
- Company Financials: Nuvation Bio reported a net loss of approximately $204.6 million over the past year, which is typical for biotech firms heavily investing in R&D, and the future success of the company hinges on its pipeline performance, making it suitable for long-term investors with a high-risk tolerance.
- Market Competition and Investment Advice: Nuvation Bio focuses on innovative oncology therapeutics, and although it was not included in The Motley Fool Stock Advisor's top investment picks, its competitive edge and R&D potential in the biotechnology sector warrant attention.
See More
Nuvation Bio Expands Market Rights, Bullish Outlook
- Analyst Optimism: As of April 8, 2026, over 90% of analysts maintain a 'Buy' rating for Nuvation Bio Inc. (NYSE:NUVB), with a consensus price target of $12 indicating a potential upside of 166.08%, reflecting strong market confidence in its future performance.
- Strategic Expansion: On April 1, 2026, Nuvation Bio Inc. secured exclusive rights to develop and market safusidenib in Japan through a deal with Daiichi Sankyo, significantly enhancing the company's competitive position in the oncology market.
- Clinical Research Support: This expansion will facilitate the ongoing Phase 3 SIGMA study in Japan, providing access to all current and future data, which is crucial for improving treatment capabilities for IDH1-mutant glioma and has significant clinical implications.
- Drug Potential: As a maintenance treatment for high-risk astrocytoma, safusidenib has demonstrated promising efficacy in Phase 1 and 2 trials, including long-lasting responses and extended progression-free survival, further solidifying Nuvation Bio's position in the biopharmaceutical sector.
See More
Investigation into Nuvation Bio Executives for Breach of Fiduciary Duties
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether Nuvation Bio Inc. executives breached their fiduciary duties to shareholders, concerning potential self-dealing that could lead to shareholder losses and corporate governance reforms.
- Legal Consultation Services: The law firm offers free consultations, allowing shareholders to contact them via email or phone to ensure their rights are enforced within a limited timeframe, demonstrating a commitment to shareholder interests.
- Importance of Shareholder Participation: The voice of shareholders is crucial, and involvement in such litigation not only helps maintain the integrity and fairness of financial markets but also fights for rightful compensation, highlighting the role of investors in corporate governance.
- Potential Compensation and Reforms: Should the investigation confirm executive misconduct, shareholders may be entitled to damages and push for necessary governance reforms to enhance company transparency and accountability.
See More
Investigation into Nuvation Bio's Fiduciary Duties
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether certain officers and directors of Nuvation Bio Inc. breached their fiduciary duties to shareholders, concerning potential self-dealing that could lead to shareholder losses and necessitate corporate governance reforms.
- Legal Consultation Services: The firm offers free consultations, allowing shareholders to contact Justin Kuehn via email or phone to ensure their rights are enforced within a limited timeframe, demonstrating the firm's commitment to shareholder interests.
- Protection of Shareholder Rights: Kuehn Law emphasizes the importance of shareholder voices, stating that participation in this investigation not only helps maintain the integrity of financial markets but also aids shareholders in seeking rightful compensation and improving corporate governance.
- Cost Coverage Commitment: Kuehn Law pledges to cover all case costs without charging investors, reducing the financial burden on shareholders and encouraging more to actively participate in protecting their rights.
See More
Investigation into Nuvation Bio Executives for Fiduciary Breach
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether certain executives of Nuvation Bio Inc. breached their fiduciary duties to shareholders, focusing on potential self-dealing that could lead to corporate governance reforms and shareholder compensation.
- Free Legal Consultation: Kuehn Law offers free legal consultations, encouraging shareholders to reach out via email or phone to express their interest in participating in the lawsuit, ensuring their rights are protected.
- Importance of Participation: The significance of shareholder involvement is highlighted as crucial for maintaining the integrity and fairness of financial markets, urging investors to actively voice their concerns to safeguard their investment interests.
- Time Limitation Warning: Shareholders are urged to contact the law firm promptly due to potential time constraints, ensuring timely action to protect their legal rights.
See More
Nuvation Bio CRO Sells 200,000 Shares Amid Strategic Options Exercise
- Insider Selling Details: Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000, reducing his direct holdings by 79.05% from 253,000 to 53,000 shares, which may raise concerns about insider confidence in the company's future prospects.
- Transaction Context: This sale followed the exercise of options, and Wentworth retains 53,000 shares along with 700,000 stock options, indicating he still holds a material economic interest in Nuvation Bio, despite the significant reduction in direct stock ownership.
- Market Reaction and Investor Sentiment: Large insider sales often alert investors; however, such transactions are common in the biotech sector, particularly when executives lock in profits through options, suggesting that market sentiment may not be significantly impacted by this sale.
- Company Financial Overview: Despite a net loss of approximately $204.6 million over the past year, Nuvation Bio's revenue from its oncology drug Ibtrozi and its diversified R&D pipeline provide potential growth opportunities for long-term investors, particularly those with a higher risk tolerance.
See More
Nuvation Bio Executive Sells 200,000 Shares
- Share Sale Details: Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 shares of Class A Common Stock on April 6, 2026, for approximately $904,000 at $4.52 per share, reducing direct ownership from 253,000 to 53,000 shares, indicating a significant divestment by an executive.
- Options Exercise and Market Reaction: The transaction involved the exercise of options with an immediate sale and no indirect entities, and while insider selling may raise market concerns, it is a planned event, suggesting that market sentiment may remain unaffected.
- Company Financials: Nuvation Bio reported a net loss of approximately $204.6 million over the past year, which is typical for biotech firms heavily investing in R&D, and the future success of the company hinges on its pipeline performance, making it suitable for long-term investors with a high-risk tolerance.
- Market Competition and Investment Advice: Nuvation Bio focuses on innovative oncology therapeutics, and although it was not included in The Motley Fool Stock Advisor's top investment picks, its competitive edge and R&D potential in the biotechnology sector warrant attention.
See More
Nuvation Bio Expands Market Rights, Bullish Outlook
- Analyst Optimism: As of April 8, 2026, over 90% of analysts maintain a 'Buy' rating for Nuvation Bio Inc. (NYSE:NUVB), with a consensus price target of $12 indicating a potential upside of 166.08%, reflecting strong market confidence in its future performance.
- Strategic Expansion: On April 1, 2026, Nuvation Bio Inc. secured exclusive rights to develop and market safusidenib in Japan through a deal with Daiichi Sankyo, significantly enhancing the company's competitive position in the oncology market.
- Clinical Research Support: This expansion will facilitate the ongoing Phase 3 SIGMA study in Japan, providing access to all current and future data, which is crucial for improving treatment capabilities for IDH1-mutant glioma and has significant clinical implications.
- Drug Potential: As a maintenance treatment for high-risk astrocytoma, safusidenib has demonstrated promising efficacy in Phase 1 and 2 trials, including long-lasting responses and extended progression-free survival, further solidifying Nuvation Bio's position in the biopharmaceutical sector.
See More
Investigation into Nuvation Bio Executives for Breach of Fiduciary Duties
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether Nuvation Bio Inc. executives breached their fiduciary duties to shareholders, concerning potential self-dealing that could lead to shareholder losses and corporate governance reforms.
- Legal Consultation Services: The law firm offers free consultations, allowing shareholders to contact them via email or phone to ensure their rights are enforced within a limited timeframe, demonstrating a commitment to shareholder interests.
- Importance of Shareholder Participation: The voice of shareholders is crucial, and involvement in such litigation not only helps maintain the integrity and fairness of financial markets but also fights for rightful compensation, highlighting the role of investors in corporate governance.
- Potential Compensation and Reforms: Should the investigation confirm executive misconduct, shareholders may be entitled to damages and push for necessary governance reforms to enhance company transparency and accountability.
See More
Investigation into Nuvation Bio's Fiduciary Duties
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether certain officers and directors of Nuvation Bio Inc. breached their fiduciary duties to shareholders, concerning potential self-dealing that could lead to shareholder losses and necessitate corporate governance reforms.
- Legal Consultation Services: The firm offers free consultations, allowing shareholders to contact Justin Kuehn via email or phone to ensure their rights are enforced within a limited timeframe, demonstrating the firm's commitment to shareholder interests.
- Protection of Shareholder Rights: Kuehn Law emphasizes the importance of shareholder voices, stating that participation in this investigation not only helps maintain the integrity of financial markets but also aids shareholders in seeking rightful compensation and improving corporate governance.
- Cost Coverage Commitment: Kuehn Law pledges to cover all case costs without charging investors, reducing the financial burden on shareholders and encouraging more to actively participate in protecting their rights.
See More
Investigation into Nuvation Bio Executives for Fiduciary Breach
- Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether certain executives of Nuvation Bio Inc. breached their fiduciary duties to shareholders, focusing on potential self-dealing that could lead to corporate governance reforms and shareholder compensation.
- Free Legal Consultation: Kuehn Law offers free legal consultations, encouraging shareholders to reach out via email or phone to express their interest in participating in the lawsuit, ensuring their rights are protected.
- Importance of Participation: The significance of shareholder involvement is highlighted as crucial for maintaining the integrity and fairness of financial markets, urging investors to actively voice their concerns to safeguard their investment interests.
- Time Limitation Warning: Shareholders are urged to contact the law firm promptly due to potential time constraints, ensuring timely action to protect their legal rights.
See More
